Information  X 
Enter a valid email address

Shire plc (SHP)

  Print      Mail a friend       Annual reports

Thursday 19 July, 2012

Shire plc

Second quarter 2012 results date notification


Second quarter 2012 results date notification - August 1, 2012

Dublin, Ireland - July 19, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPG), the
global specialty biopharmaceutical company, will announce second quarter 2012
earnings on Wednesday August 1, 2012.

Results press release will be   12:00 BST / 07:00 EDT                          
issued at:                                                                     
                                                                               
Investor conference call time:  14:00 BST / 09:00 EDT                          

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial
Officer will host the investor and analyst conference call at 14:00 BST/9:00
EDT.

The details of the conference call are as follows:

UK dial in:            08082370030                                             
                                                                               
US dial in:            1866 928 7517 or 1 718 873 9077                         
                                                                               
International dial in: +44 2031394830                                          
                                                                               
Password/Conf ID:      16001010#                                               
                                                                               
Live Webcast:          http://www.shire.com/shireplc/en/investors              

Replay:

A replay of the presentation will be available for two weeks by phone and by
webcast for three months. Details can be found on our Investor Relations
website http://www.shire.com/shireplc/en/investors.

For further information please contact:

Investor Relations  Souheil Salah (ssalah@shire.com)         +44 1256 894 160  
                                                                               
                    Erin K. Kelly (erikelly@shire.com)       +1 781 482 9541   

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder, human genetic
therapies, gastrointestinal diseases and regenerative medicine as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: 
www.shire.com.

                                                                             
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     
                                                  
www.shire.com